Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Marco Tagliamento, Carlo Genova, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Angela Alama, Simona Coco, Simona Boccardo & Francesco Grossi. (2018) Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opinion on Pharmacotherapy 19:18, pages 2055-2062.
Read now
Read now
Jian Wang, Yuxin Wen, Guanggui Ding, Peikun Ding, Lu Zhang, Jing Liu, Tengfei Zhang & Lin Yang. (2018) Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation. Cancer Biology & Therapy 19:6, pages 450-453.
Read now
Read now
Carlo Genova, Erika Rijavec, Federica Biello, Giovanni Rossi, Giulia Barletta, Maria Giovanna Dal Bello, Irene Vanni, Simona Coco, Angela Alama & Francesco Grossi. (2017) New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer. Expert Opinion on Pharmacotherapy 18:1, pages 19-33.
Read now
Read now
Pol Specenier & Jan Vermorken. (2016) Afatinib in squamous cell carcinoma of the head and neck. Expert Opinion on Pharmacotherapy 17:9, pages 1295-1301.
Read now
Read now
Aswin Somasundaram, Mark A Socinski & Timothy F Burns. (2014) Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opinion on Pharmacotherapy 15:18, pages 2693-2708.
Read now
Read now
Articles from other publishers (13)
Bing Liu, Daniela Duenas, Li Zheng, Karen Reckamp & Binghui Shen. (2021) Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer. Protein & Cell 13:2, pages 82-89.
Crossref
Crossref
Karim Amrane, Margaux Geier, Romain Corre, Hervé Léna, Guillaume Léveiller, Florence Gadby, Régine Lamy, Jean‐Louis Bizec, Eric Goarant, Gilles Robinet, Sylvie Gouva, Gilles Quere, Ronan Abgral, Ulrike Schick, Cyril Bernier, Christos Chouaid & Renaud Descourt. (2020) First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study. Cancer Medicine 9:7, pages 2309-2316.
Crossref
Crossref
Toshimitsu Yamaoka, Sojiro Kusumoto, Koichi Ando, Motoi Ohba & Tohru Ohmori. (2018) Receptor Tyrosine Kinase-Targeted Cancer Therapy. International Journal of Molecular Sciences 19:11, pages 3491.
Crossref
Crossref
Chen Fu, Dan S. Gombos, Jared Lee, Goldy C. George, Kenneth Hess, Andrew Whyte & David S. Hong. (2017) Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget 8:35, pages 58709-58727.
Crossref
Crossref
Kaoru Kaseda, Keisuke Asakura, Akio Kazama & Yukihiko Ozawa. (2017)
Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-
ras
mutation
. Thoracic Cancer 8:3, pages 229-237.
Crossref
Crossref
Felix Muth, Ahmed El-Gokha, Francesco Ansideri, Michael Eitel, Eva Döring, Adrian Sievers-Engler, Andreas Lange, Frank M. Boeckler, Michael Lämmerhofer, Pierre Koch & Stefan A. Laufer. (2017) Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3. Journal of Medicinal Chemistry 60:2, pages 594-607.
Crossref
Crossref
Ji Yun Lee, Jong-Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa-Na Song, Bo Mi Ku, Jiae Koh, Yeon-Hee Bae, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park & Myung-Ju Ahn. (2016) A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib. Clinical Cancer Research 22:9, pages 2139-2145.
Crossref
Crossref
Andrea Kinga Marias Furuya, Hamayun J. Sharifi, Robert M. Jellinger, Paul Cristofano, Binshan Shi & Carlos M. C. de Noronha. (2016) Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2. PLOS Pathogens 12:4, pages e1005581.
Crossref
Crossref
Kun-Ming Rau, Han-Ku Chen, Li-Yen Shiu, Tsai-Ling Chao, Yi-Ping Lo, Chin-Chou Wang, Meng-Chih Lin & Chao-Cheng Huang. (2016) Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. International Journal of Molecular Sciences 17:4, pages 524.
Crossref
Crossref
M.G. Dal Bello, A. Alama, G. Barletta, S. Coco, A. Truini, I. Vanni, S. Boccardo, C. Genova, E. Rijavec, F. Biello, G. Bottoni, G. Sambuceti & F. Grossi. (2015)
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in
NSCLC
cell lines poorly responsive to reversible
EGFR
tyrosine kinase inhibitors
. International Journal of Cancer 137:12, pages 2947-2958.
Crossref
Crossref
Diego Marquez-Medina & Sanjay Popat. (2015) Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Future Oncology 11:18, pages 2525-2540.
Crossref
Crossref
Simona Coco, Anna Truini, Angela Alama, Maria Giovanna Dal Bello, Roberta Venè, Anna Garuti, Enrico Carminati, Erika Rijavec, Carlo Genova, Giulia Barletta, Claudio Sini, Alberto Ballestrero, Francesco Boccardo & Francesco Grossi. (2014) Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Targeted Oncology 10:3, pages 393-404.
Crossref
Crossref
Pierre Koch, Matthias Gehringer & Stefan A. Laufer. (2014) Inhibitors of c-Jun N-Terminal Kinases: An Update. Journal of Medicinal Chemistry 58:1, pages 72-95.
Crossref
Crossref